Celldex Therapeutics Inc (CLDX) Stock: What the Analysts are Saying
The stock has a 36-month beta value of 1.59. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 1 as
The stock has a 36-month beta value of 1.59. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 1 as
Celldex Therapeutics Inc (NASDAQ: CLDX)’s stock price has decreased by -4.90 compared to its previous closing price of 28.14. However, the company has seen a
In the past week, CLDX stock has gone down by -1.64%, with a monthly decline of -8.21% and a quarterly plunge of -25.17%. The volatility
CLDX has 36-month beta value of 1.57. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,”
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.